ストックスクリーナーアプリを入手
2.59
1.17%
0.03
アフターアワーズ：
2.57
-0.02
-0.77%
前日終値:
$2.56
開ける：
$2.56
24時間の取引高:
1.34M
Relative Volume:
1.11
時価総額：
$333.27M
収益：
$564.17M
当期純損益:
$37.03M
株価収益率:
23.65
EPS:
0.1095
ネットキャッシュフロー:
$-24.46M
1週間 パフォーマンス:
+7.92%
1か月 パフォーマンス:
+15.62%
6か月 パフォーマンス:
-34.76%
1年 パフォーマンス:
-51.32%
1日の値動き範囲:
$2.54
$2.645
1週間の範囲:
$2.275
$2.73
52週間の値動き範囲:
$2.21
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Compare ORGO vs TAK, ZTS, TEVA, HLN, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.59 | 329.41M | 564.17M | 37.03M | -24.46M | 0.1095 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-28 | 開始されました | Lake Street | Buy |
| 2024-02-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-11-10 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-08-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 開始されました | SVB Leerink | Outperform |
| 2019-08-26 | 再開されました | Credit Suisse | Outperform |
| 2019-05-02 | 開始されました | Credit Suisse | Outperform |
| 2019-04-17 | 開始されました | Oppenheimer | Outperform |
| 2019-04-11 | 開始されました | SunTrust | Buy |
すべてを表示
Organogenesis Holdings Inc (ORGO) 最新ニュース
ORGO Price Today: Organogenesis Holdings Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
[ARS] Organogenesis Holdings Inc. SEC Filing - Stock Titan
Organogenesis (NASDAQ: ORGO) details 2026 virtual meeting, pay and audit votes - Stock Titan
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu® - Orthopedics This Week
Organogenesis (ORGO) Projected to Post Earnings on Thursday - MarketBeat
Organogenesis completes biologics license application for knee OA By Investing.com - Investing.com India
Organogenesis completes biologics license application for knee OA - Investing.com UK
Organogenesis Holdings Inc. Completes Biologics License Application Submission for ReNu® to Treat Knee Osteoarthritis - Quiver Quantitative
31.1M Americans have knee OA; Organogenesis sends ReNu to FDA - Stock Titan
What's going on with Organogenesis stock on Wednesday? - MSN
Organogenesis (NASDAQ:ORGO) Trading Up 1.7%Time to Buy? - MarketBeat
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis (ORGO) CCO exercises option, now holds 900,682 shares - Stock Titan
Tissue Engineering Market to Grow at 12.95% CAGR Reaching USD 27.59 Billion by 2031, Driven by Advances in Regenerative Medicine and Biomaterials, Says Mordor Intelligence - GlobeNewswire Inc.
Organogenesis Holdings Q3 2025 Earnings Preview - MSN
Organogenesis Holdings (ORGO) Stock Dark Pool Activity (Trend Weakens) 2026-04-20Shared Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Organogenesis Holdings Inc. (ORGO): Investor Outlook With A 213% Potential Upside - DirectorsTalk Interviews
Organogenesis Holdings, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
3 Penny Stocks With Market Caps Under $400M To Consider - simplywall.st
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens - The Chronicle-Journal
Options Flow: Will Organogenesis Holdings Inc benefit from rate cuts2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
720p-h264Dailyhunt - Dailyhunt
What's Going On With Organogenesis Stock On Wednesday? - Sahm
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight (NASDAQ:ORGO) - Seeking Alpha
Organogenesis stock rockets after diabetic foot ulcer trial posts statistically significant win - MSN
PuraPly AM Triumphs in Wound Healing Trial, Paves Way for New Successes - StocksToTrade
Organogenesis’ Clinical Trials Propel Stock Amid FDA Progress - timothysykes.com
Organogenesis stock surges 20% on trial results By Investing.com - Investing.com Australia
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win - Benzinga
Organogenesis stock surges 20% on trial results - Investing.com
Organogenesis Holdings Inc (ORGO) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
2.13%
大文字化:
|
ボリューム (24 時間):